C4X Discovery Holdings PLC 2018 Annual Report (1270K)
December 11 2018 - 5:48AM
UK Regulatory
TIDMC4XD
RNS Number : 1270K
C4X Discovery Holdings PLC
11 December 2018
C4X Discovery Holdings plc
(C4XD, C4X Discovery or the Company)
2018 Annual Report
11 December 2018 - C4X Discovery Holdings plc (AIM: C4XD), a
pioneering drug discovery company, announces that the Annual Report
and Financial Statements for the year ended 31 July 2018, has been
published and sent to shareholders.
A copy of the 2018 Annual Report can be viewed on, and
downloaded from, the Company's website at
https://www.c4xdiscovery.com.
-ENDS-
For further information, please contact:
C4X Discovery Holdings plc
+44 (0)7801 865 803
Clive Dix, Chief Executive Officer
Panmure Gordon (UK) Limited (NOMAD and Broker) +44 (0)20 7886
2500
Freddy Crossley, Emma Earl (Corporate Finance)
James Stearns (Corporate Broking)
Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal +44 (0)203 709
5700
About C4X Discovery
C4X Discovery aims to become the world's most productive drug
discovery engine by exploiting cutting edge technologies to design
and create best-in-class small-molecule candidates targeting a
range of high value therapeutic areas. The company's goal is to
drive returns through early-stage revenue-generating deals with the
pharmaceutical industry.
C4X Discovery has a state-of-the-art suite of proprietary
technologies across the drug discovery process. The company's
innovative DNA-based target identification platform (Taxonomy3(R))
utilises human genetic datasets to identify novel patient-specific
targets leading to greater discovery productivity and increased
probability of clinical success. This is complemented by C4XD's
novel drug design platform which comprises two innovative chemistry
technologies, Conformetrix and Molplex, that combine 4D molecular
shape analyses (based on experimental data) with best-in-class
computational chemistry. This provides new and unprecedented
insight into the behaviour of drug molecules, enabling the
production of potent selective compounds faster and more cost
effectively than the industry standard.
C4X Discovery is advancing its in-house pipeline that is
primarily focused on the high value therapeutic areas of
inflammation, neurodegeneration and cancer (including
immuno-oncology) with a number of new drug candidates identified
and further progress made towards the pre-clinical licensing
discussions. In selecting new targets and executing new drug
discovery programmes, C4X Discovery focuses on high-value disease
areas that are the subject of significant licensing activity and
will continue to also maximise value from opportunistic areas such
as addiction and diabetes. The Company recently signed a licensing
agreement with Indivior for a pre-clinical addiction programme
worth up to $294m.
The Company was founded as a spin-out from the University of
Manchester. It has a highly experienced management team and Board
who have delivered significant value creation within the healthcare
sector historically and have enabled C4XD to reach multiple value
inflexion points since IPO. For additional information please go
to: www.c4xdiscovery.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ACSUASARWSAUAAA
(END) Dow Jones Newswires
December 11, 2018 06:48 ET (11:48 GMT)
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From Apr 2024 to May 2024
C4x Discovery (LSE:C4XD)
Historical Stock Chart
From May 2023 to May 2024